Lack of bioequivalence of a generic mefloquine tablet with the standard product

European Journal of Clinical Pharmacology

Volumn 54, Issue 8, 1998, Pages 615-619

  Weidekamm, E ^a   Rusing G ^b   Caplain, H ^c   Sorgel F ^b   Crevoisier, C ^d  

^a Clin Pharma Research AG   (Switzerland)

^b IBMP Institute for Biomedical and Pharmaceutical Research   (Germany)

^c Aster Clinical Research Center   (France)

^d F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

Bioavailability; Bioinequivalence; Mefloquine

Indexed keywords

MEFLOQUINE;

ARTICLE; BIOEQUIVALENCE; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG ELIMINATION; HUMAN; MALARIA; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; ADULT; CROSS-OVER STUDIES; DRUGS, GENERIC; FASTING; FEMALE; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HUMANS; MALE; MEFLOQUINE; SOLUBILITY; THERAPEUTIC EQUIVALENCY;

EID: 0031797279     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002280050523     Document Type: Article

References (13)

1. Karbwang J, White NJ (1990) Clinical pharmacokinetics of mefloquine. Clin Pharmacokinet 19: 264-279
2. White NJ (1988) Drug treatment and prevention of malaria. Eur J Clin Pharmacol 34: 1-14
3. Palmer KJ, Holliday SM, Brodgen RN (1993) Mefloquine - a review of its antimalarial activity, pharmacokinetic properties and therapeutic efficacy. Drugs 45: 430-475
4. Lobel HO, Miani M, Eng T. Bernhard KW, Hightower AW, Campbell CC (1993) Long-term malaria prophylaxis with weekly mefloquine. Lancet 341: 848-851
5. Lobel HO, Bernard KW, Williams SL, Hightower AW, Patehen LC, Campbell CC (1991) Effectiveness and tolerance of long-term malaria prophylaxis with mefloquine: need for a better dosing regimen. JAMA 265: 361-364
6. Gibaldi M, Perrier D (1982) Pharmacokinetics. Marcel Dekker, New York
7. Schuirmann DJ (1987) A comparison of the two one-sided tests procedure and the power approach for assessing equivalence of average bioavailability. J Pharmacokinet Biopharm 15: 657-680
8. Crevoisier C, Handschin J, Barré J, Roumenov D, Kleinbloesem C (1997) Food increases the bioavailability of mefloquine. Eur J Clin Pharmacol 53: 135-139
9. Basco LK, Gillotin C, Gimenez F, Farinotti R, LeBras J (1991) Absence of antimalarial activity or interaction with mefloquine enantiomers in vitro of the main human metabolite of mefloquine. Trans R Soc Trop Med Hyg 85: 208-209
10. Slutsker LM, Khoromana CO, Payne D, Allen CR, Wirima JJ, Heymann DL, Patahen L, Steketee RW (1990). Mefloquine therapy for Plasmodium falciparum malaria in children under 5 years of age in Malawi: in vivo in vitro efficacy and correlation of drug concentration with parasitological outcome. Bull World Health Organ 68: 53-59
11. Desjardins RE, Pamplin III CL, von Bredow J, Barry KG, Canfield CJ (1979) Kinetics of a new antimalarial, mefloquine. Clin Pharmacol Ther 26: 372-379
12. Franssen G, Rouveix B, Lebras J, Bauchet J, Verdier F, Michon C, Bricaire F (1989) Divided-dose kinetics of mefloquine in man. Br J Clin Pharmacol 28: 179-184
13. Boudreau E, Schuster B, Sanchez J, Novakowski W, Johnson R, Redmont D, Hanson R, Dausel L (1993) Tolerability of prophylactic Lariam regimens. Trop Med Parasitol 44: 257-265